Skip to main content
. 2023 Apr 12;616(7957):525–533. doi: 10.1038/s41586-023-05783-5

Fig. 4. Associations between ITH and prognosis in the TRACERx 421 cohort.

Fig. 4

a, The difference in DFS between 392 patients harbouring tumours with greater or less than the median value of SCNA ITH; that is, the fraction of the aberrant genome with subclonal SCNAs (Methods). The number of patients at risk in each group is indicated below each timepoint. b, The difference in DFS between 392 patients harbouring tumours with greater or less than the median value of mutational ITH; that is, the percentage of mutations which are subclonal (Methods). c, Proportions of intrathoracic only versus extrathoracic metastatic sites in 132 patients that relapsed either <1 year or ≥1 year after diagnosis split by SCNA ITH status. d, The difference in DFS in 392 patients harbouring tumours with different WGD statuses. e, The difference in DFS between 392 patients harbouring tumours with greater or less than the median value of the recent subclonal expansion score (Methods). f, A multivariable Cox proportional hazards model including subclonal WGD, SCNA ITH, recent subclonal expansion score and other clinical variables that are known to have an impact on outcome for 392 patients (Methods). HR 95% CIs are indicated in parentheses. Asterisks indicate P value ranges: *P < 0.05, **P < 0.01, ***P < 0.001. Error bars indicate 95% CIs.